Overview

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Status:
Recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This study is the first clinical study of Neoadjuvant and Adjuvant treatment of head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with PD-1 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Treatments:

Cetuximab